Essa drops lead cancer drug after falling short against Xtandi
04 Nov 2024 //
FIERCE BIOTECH
Essa Pharma Terminates Ph 2 Study of Masofaniten in Prostate Cancer
31 Oct 2024 //
PR NEWSWIRE
ESSA Pharma Reports Q3 2024 Financial Results And Updates
05 Aug 2024 //
PR NEWSWIRE
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data
25 Jan 2024 //
PR NEWSWIRE
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data
21 Oct 2023 //
PR NEWSWIRE
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten
18 Sep 2023 //
PR NEWSWIRE